Mrudula Borse is interested in real world evidence and health technology assessment.
Recent Papers and Presentations:
1. Borse M, Dong OM, Polasek MJ, et al. CYP2C19 guided antiplatelet therapy: a cost effectiveness analysis of 30 day and one year outcomes following percutaneous coronary intervention. Journal of Pharmacogenomics and Personalized Medicine. 2017.
2. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. The Annals of pharmacotherapy. 2013-12; 47:1675-84
UNC/GlaxoSmithKline US Health Outcomes Fellowships
Year Admitted: 2012
Adviser: Joel Farley